MORF Morphic Holding Inc

Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the Jefferies Healthcare Conference, including a hosted fireside chat, on Wednesday, June 7, 2023.

Fireside Chat InformationDate: Wednesday June 7, 2023Time: 1:00 PM ETA live webcast of the presentation will be available on the Investor section of the Morphic website, or at the link here. An archived replay will be available on the company’s website following the conference.

About Morphic TherapeuticMorphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

ContactsMorphic TherapeuticChris Erdmanchris.erdman@morphictx.com617.686.1718